| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biodiversity | 130 | 2023 | 341 | 20.580 |
Why?
|
| Disease Transmission, Infectious | 38 | 2022 | 547 | 11.970 |
Why?
|
| Mycobacterium tuberculosis | 107 | 2024 | 1832 | 11.250 |
Why?
|
| Coronavirus Infections | 43 | 2020 | 3133 | 8.970 |
Why?
|
| Pneumonia, Viral | 42 | 2020 | 3240 | 8.530 |
Why?
|
| Immunization, Secondary | 17 | 2022 | 340 | 8.150 |
Why?
|
| Communicable Disease Control | 22 | 2022 | 857 | 6.530 |
Why?
|
| Viral Vaccines | 19 | 2023 | 636 | 6.230 |
Why?
|
| Mycobacterium smegmatis | 28 | 2024 | 122 | 6.220 |
Why?
|
| Tuberculosis | 44 | 2023 | 1912 | 5.810 |
Why?
|
| Global Warming | 28 | 2022 | 64 | 5.380 |
Why?
|
| Pandemics | 48 | 2023 | 8388 | 4.930 |
Why?
|
| Antiviral Agents | 19 | 2022 | 2987 | 4.880 |
Why?
|
| Immunization Programs | 9 | 2022 | 260 | 4.710 |
Why?
|
| Temperature | 110 | 2023 | 2206 | 4.370 |
Why?
|
| Public Health Practice | 11 | 2022 | 218 | 4.300 |
Why?
|
| Mycobacterium | 16 | 2023 | 249 | 4.200 |
Why?
|
| Editorial Policies | 19 | 2022 | 451 | 4.180 |
Why?
|
| Bacterial Proteins | 57 | 2024 | 3848 | 4.150 |
Why?
|
| Antitubercular Agents | 35 | 2023 | 1320 | 3.960 |
Why?
|
| Antibodies, Monoclonal | 21 | 2022 | 9274 | 3.240 |
Why?
|
| Periodicals as Topic | 23 | 2022 | 1432 | 3.180 |
Why?
|
| Adenosine Monophosphate | 7 | 2021 | 275 | 3.170 |
Why?
|
| Clinical Laboratory Techniques | 7 | 2020 | 738 | 3.140 |
Why?
|
| Alanine | 8 | 2021 | 572 | 3.130 |
Why?
|
| Antibodies, Viral | 20 | 2022 | 3176 | 2.740 |
Why?
|
| Journalism, Medical | 4 | 2023 | 74 | 2.610 |
Why?
|
| Cell Wall | 19 | 2022 | 422 | 2.600 |
Why?
|
| Biomedical Research | 14 | 2023 | 3309 | 2.530 |
Why?
|
| Fever | 24 | 2021 | 1616 | 2.460 |
Why?
|
| Peptidoglycan | 11 | 2022 | 246 | 2.350 |
Why?
|
| International Cooperation | 13 | 2023 | 1420 | 2.290 |
Why?
|
| Clinical Trials as Topic | 19 | 2022 | 7913 | 2.230 |
Why?
|
| Masks | 4 | 2022 | 197 | 2.200 |
Why?
|
| Humans | 422 | 2023 | 744343 | 2.160 |
Why?
|
| N-Acetylmuramoyl-L-alanine Amidase | 5 | 2019 | 47 | 2.090 |
Why?
|
| Hydroxychloroquine | 6 | 2020 | 412 | 2.080 |
Why?
|
| Public Health | 14 | 2023 | 2603 | 2.010 |
Why?
|
| Genome, Bacterial | 17 | 2024 | 760 | 1.960 |
Why?
|
| Climate Change | 15 | 2022 | 418 | 1.960 |
Why?
|
| Immunocompromised Host | 5 | 2022 | 847 | 1.930 |
Why?
|
| Immunization, Passive | 9 | 2021 | 623 | 1.890 |
Why?
|
| Vaccination | 15 | 2022 | 3278 | 1.810 |
Why?
|
| Information Dissemination | 5 | 2021 | 1099 | 1.760 |
Why?
|
| Antibiotics, Antitubercular | 5 | 2022 | 104 | 1.750 |
Why?
|
| Conservation of Natural Resources | 10 | 2022 | 204 | 1.700 |
Why?
|
| Antibodies, Neutralizing | 14 | 2022 | 1978 | 1.660 |
Why?
|
| Mass Media | 4 | 2021 | 305 | 1.600 |
Why?
|
| Drug Resistance, Bacterial | 15 | 2022 | 1035 | 1.590 |
Why?
|
| United States Food and Drug Administration | 7 | 2022 | 1584 | 1.540 |
Why?
|
| DNA Transposable Elements | 20 | 2017 | 748 | 1.520 |
Why?
|
| Communication | 8 | 2022 | 3749 | 1.500 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2021 | 1790 | 1.460 |
Why?
|
| Immunity, Mucosal | 3 | 2022 | 490 | 1.460 |
Why?
|
| Dexamethasone | 7 | 2021 | 1951 | 1.460 |
Why?
|
| Rifampin | 5 | 2021 | 315 | 1.450 |
Why?
|
| Quarantine | 6 | 2021 | 170 | 1.440 |
Why?
|
| Drug Discovery | 12 | 2022 | 1058 | 1.430 |
Why?
|
| Cell Division | 11 | 2019 | 4568 | 1.430 |
Why?
|
| Disclosure | 13 | 2020 | 736 | 1.430 |
Why?
|
| Contact Tracing | 3 | 2020 | 273 | 1.400 |
Why?
|
| Virulence | 22 | 2022 | 1333 | 1.400 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2021 | 224 | 1.390 |
Why?
|
| World Health Organization | 4 | 2022 | 1318 | 1.290 |
Why?
|
| Healthcare Disparities | 7 | 2022 | 3158 | 1.280 |
Why?
|
| Genes, Bacterial | 17 | 2020 | 1079 | 1.260 |
Why?
|
| Vaccines | 5 | 2022 | 822 | 1.230 |
Why?
|
| Patient Care | 4 | 2022 | 640 | 1.220 |
Why?
|
| Immunologic Factors | 3 | 2021 | 1580 | 1.220 |
Why?
|
| Hemorrhagic Fever, Ebola | 5 | 2022 | 428 | 1.200 |
Why?
|
| Anti-Bacterial Agents | 17 | 2023 | 7181 | 1.190 |
Why?
|
| Cocaine-Related Disorders | 17 | 2021 | 460 | 1.190 |
Why?
|
| Bacteria | 7 | 2014 | 2114 | 1.180 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2021 | 652 | 1.140 |
Why?
|
| Public Policy | 2 | 2022 | 572 | 1.140 |
Why?
|
| Microbial Sensitivity Tests | 16 | 2020 | 1877 | 1.120 |
Why?
|
| Drug Approval | 6 | 2022 | 742 | 1.110 |
Why?
|
| Bacteriophages | 8 | 2023 | 356 | 1.100 |
Why?
|
| Evolution, Molecular | 8 | 2022 | 1940 | 1.100 |
Why?
|
| Mutagenesis, Insertional | 13 | 2017 | 655 | 1.100 |
Why?
|
| Virus Replication | 12 | 2022 | 2534 | 1.080 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 612 | 1.050 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2020 | 810 | 1.040 |
Why?
|
| Mass Vaccination | 3 | 2021 | 105 | 1.040 |
Why?
|
| Conflict of Interest | 9 | 2020 | 544 | 1.040 |
Why?
|
| Federal Government | 3 | 2021 | 260 | 1.020 |
Why?
|
| Emergencies | 6 | 2023 | 1170 | 1.020 |
Why?
|
| Health Services Accessibility | 8 | 2022 | 5137 | 1.000 |
Why?
|
| Drug Resistance, Viral | 4 | 2022 | 820 | 1.000 |
Why?
|
| Minority Groups | 3 | 2021 | 1223 | 1.000 |
Why?
|
| Medicine | 2 | 2023 | 946 | 1.000 |
Why?
|
| Glucocorticoids | 4 | 2021 | 2107 | 0.990 |
Why?
|
| Israel | 6 | 2021 | 796 | 0.990 |
Why?
|
| Consumer Health Information | 3 | 2021 | 211 | 0.990 |
Why?
|
| Genetic Vectors | 12 | 2022 | 3420 | 0.980 |
Why?
|
| Vaccines, Synthetic | 3 | 2022 | 634 | 0.980 |
Why?
|
| Ritonavir | 3 | 2022 | 322 | 0.970 |
Why?
|
| Thrombosis | 4 | 2021 | 2968 | 0.960 |
Why?
|
| Myocarditis | 2 | 2021 | 771 | 0.940 |
Why?
|
| Serine Endopeptidases | 5 | 2019 | 1072 | 0.920 |
Why?
|
| Drug Industry | 4 | 2022 | 746 | 0.920 |
Why?
|
| Endopeptidase Clp | 4 | 2021 | 47 | 0.910 |
Why?
|
| Attitude to Health | 3 | 2021 | 2052 | 0.900 |
Why?
|
| Emergency Service, Hospital | 32 | 2021 | 7659 | 0.900 |
Why?
|
| State Government | 3 | 2021 | 372 | 0.890 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 19 | 0.870 |
Why?
|
| Infection Control | 5 | 2021 | 966 | 0.870 |
Why?
|
| Health Education | 7 | 2022 | 1056 | 0.860 |
Why?
|
| Vaccines, Combined | 1 | 2022 | 69 | 0.860 |
Why?
|
| Penicillin-Binding Proteins | 4 | 2022 | 137 | 0.850 |
Why?
|
| Fossil Fuels | 1 | 2022 | 44 | 0.850 |
Why?
|
| Hydroxylamines | 1 | 2021 | 40 | 0.830 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2023 | 93 | 0.830 |
Why?
|
| Antitoxins | 1 | 2022 | 81 | 0.830 |
Why?
|
| Developed Countries | 8 | 2022 | 437 | 0.820 |
Why?
|
| United States | 33 | 2023 | 69872 | 0.810 |
Why?
|
| Hospitalization | 7 | 2022 | 10262 | 0.810 |
Why?
|
| Cytidine | 1 | 2021 | 68 | 0.810 |
Why?
|
| Genes, Essential | 7 | 2019 | 183 | 0.790 |
Why?
|
| Lactams | 1 | 2022 | 156 | 0.780 |
Why?
|
| Asymptomatic Diseases | 5 | 2021 | 551 | 0.780 |
Why?
|
| Mandatory Programs | 1 | 2021 | 87 | 0.770 |
Why?
|
| Patient Selection | 3 | 2022 | 4215 | 0.770 |
Why?
|
| Tobacco Industry | 1 | 2022 | 126 | 0.770 |
Why?
|
| Mutation | 27 | 2023 | 29786 | 0.770 |
Why?
|
| Health Care Rationing | 2 | 2021 | 437 | 0.760 |
Why?
|
| Oxazoles | 5 | 2015 | 189 | 0.760 |
Why?
|
| Granuloma | 2 | 2016 | 319 | 0.760 |
Why?
|
| Politics | 3 | 2021 | 791 | 0.740 |
Why?
|
| Time Factors | 22 | 2023 | 40075 | 0.740 |
Why?
|
| Social Isolation | 2 | 2021 | 365 | 0.740 |
Why?
|
| Viral Load | 8 | 2021 | 3299 | 0.740 |
Why?
|
| Leucine | 1 | 2022 | 561 | 0.730 |
Why?
|
| Epoprostenol | 1 | 2021 | 254 | 0.730 |
Why?
|
| Host-Pathogen Interactions | 6 | 2019 | 1477 | 0.730 |
Why?
|
| Choice Behavior | 5 | 2022 | 803 | 0.730 |
Why?
|
| Adenoviridae | 5 | 2021 | 1099 | 0.720 |
Why?
|
| Proline | 1 | 2022 | 458 | 0.720 |
Why?
|
| Anti-Infective Agents | 2 | 2020 | 972 | 0.720 |
Why?
|
| Cytoplasm | 2 | 2016 | 1539 | 0.720 |
Why?
|
| Environmental Health | 5 | 2021 | 278 | 0.720 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 552 | 0.710 |
Why?
|
| Latent Tuberculosis | 4 | 2019 | 225 | 0.710 |
Why?
|
| Organelles | 1 | 2021 | 264 | 0.710 |
Why?
|
| Oxygen | 3 | 2021 | 4189 | 0.710 |
Why?
|
| Virulence Factors | 8 | 2020 | 509 | 0.700 |
Why?
|
| Disease Outbreaks | 5 | 2022 | 1772 | 0.700 |
Why?
|
| Epidemics | 4 | 2021 | 523 | 0.700 |
Why?
|
| South Africa | 6 | 2022 | 1731 | 0.700 |
Why?
|
| Azetidines | 1 | 2020 | 142 | 0.690 |
Why?
|
| Periplasmic Proteins | 1 | 2019 | 25 | 0.690 |
Why?
|
| Science | 1 | 2022 | 241 | 0.690 |
Why?
|
| Mandatory Reporting | 1 | 2020 | 121 | 0.690 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2020 | 187 | 0.690 |
Why?
|
| Microbial Viability | 6 | 2019 | 234 | 0.680 |
Why?
|
| Authorship | 10 | 2020 | 271 | 0.680 |
Why?
|
| Social Justice | 1 | 2023 | 456 | 0.680 |
Why?
|
| Health Communication | 1 | 2022 | 214 | 0.670 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 687 | 0.670 |
Why?
|
| Tryptophan | 4 | 2021 | 478 | 0.660 |
Why?
|
| Prodrugs | 3 | 2017 | 268 | 0.660 |
Why?
|
| Mycobacterium bovis | 7 | 2023 | 150 | 0.660 |
Why?
|
| Macrophages | 18 | 2023 | 5655 | 0.660 |
Why?
|
| Mutagenesis | 6 | 2022 | 1266 | 0.650 |
Why?
|
| Mycobacterium marinum | 2 | 2009 | 26 | 0.650 |
Why?
|
| Private Sector | 1 | 2021 | 392 | 0.650 |
Why?
|
| Gene Expression Regulation, Bacterial | 12 | 2024 | 1122 | 0.640 |
Why?
|
| Viruses | 1 | 2022 | 374 | 0.640 |
Why?
|
| Research Support as Topic | 3 | 2021 | 705 | 0.640 |
Why?
|
| Iron | 6 | 2019 | 1774 | 0.640 |
Why?
|
| Ethics, Medical | 1 | 2023 | 792 | 0.640 |
Why?
|
| Health Planning | 1 | 2020 | 238 | 0.640 |
Why?
|
| Nitriles | 2 | 2022 | 956 | 0.630 |
Why?
|
| Animal Experimentation | 1 | 2018 | 45 | 0.630 |
Why?
|
| Publishing | 3 | 2022 | 833 | 0.620 |
Why?
|
| United Nations | 7 | 2022 | 165 | 0.620 |
Why?
|
| Cultural Diversity | 1 | 2021 | 359 | 0.620 |
Why?
|
| Adaptive Immunity | 3 | 2020 | 713 | 0.610 |
Why?
|
| Pyrazoles | 2 | 2020 | 1972 | 0.610 |
Why?
|
| Ethionamide | 1 | 2017 | 11 | 0.610 |
Why?
|
| Immunity, Herd | 3 | 2022 | 44 | 0.600 |
Why?
|
| Lipid A | 2 | 2015 | 67 | 0.600 |
Why?
|
| Purines | 1 | 2020 | 594 | 0.600 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2018 | 602 | 0.600 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2018 | 92 | 0.600 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 253 | 0.590 |
Why?
|
| Health Resources | 2 | 2021 | 911 | 0.590 |
Why?
|
| Vaccines, Attenuated | 4 | 2020 | 342 | 0.580 |
Why?
|
| Spiro Compounds | 1 | 2017 | 76 | 0.580 |
Why?
|
| Molecular Biology | 2 | 2014 | 596 | 0.580 |
Why?
|
| Bacterial Toxins | 2 | 2022 | 931 | 0.580 |
Why?
|
| Heat-Shock Proteins | 3 | 2020 | 822 | 0.580 |
Why?
|
| Thrombocytopenia | 6 | 2021 | 1179 | 0.580 |
Why?
|
| Vaccines, Inactivated | 3 | 2021 | 184 | 0.570 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 380 | 0.560 |
Why?
|
| Cocaine | 11 | 2021 | 1007 | 0.560 |
Why?
|
| Research Personnel | 1 | 2021 | 573 | 0.560 |
Why?
|
| Drug Design | 7 | 2021 | 1076 | 0.560 |
Why?
|
| Biological Evolution | 1 | 2022 | 1076 | 0.550 |
Why?
|
| Nursing Homes | 2 | 2021 | 1036 | 0.550 |
Why?
|
| Escherichia coli | 12 | 2019 | 4217 | 0.540 |
Why?
|
| Isoxazoles | 1 | 2017 | 216 | 0.540 |
Why?
|
| Specimen Handling | 1 | 2020 | 694 | 0.520 |
Why?
|
| Endopeptidases | 2 | 2010 | 772 | 0.520 |
Why?
|
| Research Design | 5 | 2022 | 5987 | 0.520 |
Why?
|
| Genetic Variation | 5 | 2021 | 6544 | 0.520 |
Why?
|
| Disaster Planning | 4 | 2022 | 549 | 0.510 |
Why?
|
| Health Policy | 3 | 2022 | 2661 | 0.510 |
Why?
|
| Ebolavirus | 2 | 2014 | 263 | 0.510 |
Why?
|
| Isoniazid | 2 | 2014 | 274 | 0.510 |
Why?
|
| Commerce | 1 | 2020 | 592 | 0.500 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2022 | 1821 | 0.500 |
Why?
|
| Drug Evaluation | 3 | 2020 | 647 | 0.500 |
Why?
|
| Public Health Administration | 3 | 2022 | 240 | 0.500 |
Why?
|
| Interferon-gamma | 4 | 2013 | 3206 | 0.500 |
Why?
|
| Genetics, Microbial | 1 | 2014 | 60 | 0.500 |
Why?
|
| Treatment Outcome | 20 | 2022 | 63114 | 0.500 |
Why?
|
| Molecular Imaging | 1 | 2021 | 828 | 0.490 |
Why?
|
| Multienzyme Complexes | 3 | 2015 | 686 | 0.490 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 1855 | 0.490 |
Why?
|
| Mutagenesis, Site-Directed | 6 | 2019 | 1723 | 0.490 |
Why?
|
| Siderophores | 4 | 2019 | 57 | 0.480 |
Why?
|
| Eicosanoids | 1 | 2016 | 279 | 0.480 |
Why?
|
| Membrane Transport Proteins | 3 | 2016 | 1028 | 0.480 |
Why?
|
| Bacterial Secretion Systems | 1 | 2014 | 38 | 0.480 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 528 | 0.470 |
Why?
|
| Communicable Diseases | 1 | 2022 | 880 | 0.470 |
Why?
|
| Iron Chelating Agents | 1 | 2015 | 139 | 0.470 |
Why?
|
| Escherichia coli Proteins | 5 | 2018 | 1050 | 0.470 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2021 | 367 | 0.470 |
Why?
|
| Cell Polarity | 1 | 2017 | 645 | 0.470 |
Why?
|
| Mining | 1 | 2014 | 88 | 0.450 |
Why?
|
| Antigens, Viral | 4 | 2021 | 1035 | 0.450 |
Why?
|
| Health Personnel | 6 | 2023 | 3218 | 0.450 |
Why?
|
| Acyltransferases | 2 | 2017 | 294 | 0.450 |
Why?
|
| Antigens, Bacterial | 7 | 2023 | 1171 | 0.450 |
Why?
|
| Physician's Role | 1 | 2020 | 943 | 0.440 |
Why?
|
| Lipoproteins | 4 | 2019 | 878 | 0.440 |
Why?
|
| Faculty, Medical | 1 | 2021 | 1181 | 0.440 |
Why?
|
| Animals | 69 | 2023 | 168757 | 0.430 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 232 | 0.430 |
Why?
|
| Mycobacteriophages | 2 | 2023 | 19 | 0.430 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 1199 | 0.430 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 214 | 0.430 |
Why?
|
| Pyrimidinones | 1 | 2015 | 371 | 0.430 |
Why?
|
| Goals | 1 | 2018 | 706 | 0.430 |
Why?
|
| Leadership | 2 | 2021 | 1357 | 0.430 |
Why?
|
| Drug Therapy, Combination | 5 | 2022 | 6489 | 0.420 |
Why?
|
| Endotoxins | 1 | 2015 | 527 | 0.420 |
Why?
|
| Trust | 3 | 2021 | 505 | 0.420 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 2569 | 0.410 |
Why?
|
| Mycobacterium Infections | 4 | 2018 | 119 | 0.410 |
Why?
|
| History, 21st Century | 3 | 2023 | 1534 | 0.410 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2008 | 3920 | 0.410 |
Why?
|
| Cell Physiological Phenomena | 1 | 2013 | 154 | 0.410 |
Why?
|
| Polymerase Chain Reaction | 7 | 2014 | 6171 | 0.400 |
Why?
|
| Microcephaly | 1 | 2016 | 432 | 0.400 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 2046 | 0.400 |
Why?
|
| Molecular Sequence Data | 25 | 2015 | 18111 | 0.390 |
Why?
|
| Inflammation | 5 | 2021 | 10638 | 0.390 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2021 | 3022 | 0.390 |
Why?
|
| RNA, Transfer | 3 | 2023 | 316 | 0.390 |
Why?
|
| Endemic Diseases | 2 | 2022 | 182 | 0.390 |
Why?
|
| Sulfonamides | 1 | 2020 | 1938 | 0.390 |
Why?
|
| Age Factors | 9 | 2021 | 18370 | 0.390 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 14722 | 0.390 |
Why?
|
| Pneumonia | 1 | 2023 | 2133 | 0.380 |
Why?
|
| Peptide Hydrolases | 3 | 2012 | 634 | 0.380 |
Why?
|
| Selection, Genetic | 3 | 2022 | 914 | 0.380 |
Why?
|
| Forecasting | 4 | 2023 | 2951 | 0.380 |
Why?
|
| Oligopeptides | 5 | 2021 | 1189 | 0.370 |
Why?
|
| Protein Biosynthesis | 2 | 2018 | 2126 | 0.370 |
Why?
|
| Child | 13 | 2022 | 77709 | 0.370 |
Why?
|
| Multigene Family | 1 | 2014 | 1102 | 0.370 |
Why?
|
| Disease Reservoirs | 2 | 2021 | 131 | 0.370 |
Why?
|
| Aminosalicylic Acid | 2 | 2013 | 21 | 0.370 |
Why?
|
| Hydrolases | 2 | 2023 | 139 | 0.370 |
Why?
|
| Fetal Diseases | 1 | 2016 | 903 | 0.370 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 1537 | 0.370 |
Why?
|
| Peptidoglycan Glycosyltransferase | 1 | 2010 | 65 | 0.360 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 15540 | 0.360 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 382 | 0.360 |
Why?
|
| Virus Shedding | 2 | 2020 | 108 | 0.360 |
Why?
|
| Lipopolysaccharides | 3 | 2015 | 2216 | 0.360 |
Why?
|
| Lipids | 5 | 2019 | 3305 | 0.350 |
Why?
|
| Gene Library | 5 | 2017 | 1074 | 0.350 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2214 | 0.350 |
Why?
|
| Africa | 2 | 2022 | 673 | 0.350 |
Why?
|
| Camptothecin | 4 | 1999 | 576 | 0.350 |
Why?
|
| Smoking | 6 | 2022 | 8987 | 0.350 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 1990 | 0.350 |
Why?
|
| Developing Countries | 1 | 2022 | 2815 | 0.340 |
Why?
|
| Comorbidity | 3 | 2020 | 10388 | 0.340 |
Why?
|
| Reactive Oxygen Species | 3 | 2016 | 2077 | 0.340 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 971 | 0.340 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 2291 | 0.330 |
Why?
|
| Pyrazinamide | 2 | 2020 | 54 | 0.330 |
Why?
|
| Pregnancy | 6 | 2021 | 29144 | 0.330 |
Why?
|
| Amino Acids | 3 | 2018 | 1736 | 0.330 |
Why?
|
| Air Pollution | 1 | 2022 | 2286 | 0.320 |
Why?
|
| Plasmids | 7 | 2008 | 2307 | 0.320 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 2716 | 0.320 |
Why?
|
| DNA, Bacterial | 7 | 2021 | 1465 | 0.320 |
Why?
|
| Aminoglycosides | 2 | 2018 | 162 | 0.320 |
Why?
|
| Air Pollutants | 1 | 2022 | 2817 | 0.320 |
Why?
|
| DNA Topoisomerases, Type I | 3 | 1999 | 102 | 0.320 |
Why?
|
| Mycolic Acids | 3 | 2019 | 54 | 0.310 |
Why?
|
| Placebos | 4 | 2021 | 1676 | 0.310 |
Why?
|
| Prisoners | 2 | 2021 | 297 | 0.310 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2010 | 1861 | 0.310 |
Why?
|
| Chemoprevention | 2 | 2020 | 319 | 0.310 |
Why?
|
| Cytokines | 3 | 2021 | 7322 | 0.310 |
Why?
|
| Bacteremia | 1 | 2014 | 962 | 0.310 |
Why?
|
| Tuberculosis Vaccines | 3 | 2020 | 50 | 0.310 |
Why?
|
| Piperidines | 3 | 2021 | 1602 | 0.300 |
Why?
|
| Phagosomes | 2 | 2019 | 193 | 0.300 |
Why?
|
| Infusions, Intravenous | 4 | 2021 | 2274 | 0.300 |
Why?
|
| Carrier State | 2 | 2021 | 518 | 0.300 |
Why?
|
| RNA, Bacterial | 4 | 2015 | 390 | 0.300 |
Why?
|
| Drug Interactions | 2 | 2022 | 1460 | 0.300 |
Why?
|
| Hot Temperature | 3 | 2021 | 1354 | 0.300 |
Why?
|
| Sequence Analysis, DNA | 12 | 2013 | 4803 | 0.290 |
Why?
|
| Phenotype | 9 | 2017 | 16365 | 0.290 |
Why?
|
| Plasma | 2 | 2020 | 575 | 0.290 |
Why?
|
| Chromosomes, Bacterial | 3 | 2005 | 282 | 0.290 |
Why?
|
| Biotin | 2 | 2023 | 254 | 0.290 |
Why?
|
| Transcription, Genetic | 10 | 2017 | 7722 | 0.290 |
Why?
|
| Transformation, Bacterial | 2 | 2007 | 78 | 0.290 |
Why?
|
| Disease Management | 1 | 2017 | 2459 | 0.290 |
Why?
|
| Transposases | 4 | 2001 | 107 | 0.290 |
Why?
|
| Gene Expression Profiling | 5 | 2012 | 9438 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 9959 | 0.290 |
Why?
|
| Mass Spectrometry | 7 | 2016 | 2203 | 0.290 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2183 | 0.290 |
Why?
|
| Base Sequence | 18 | 2012 | 12797 | 0.280 |
Why?
|
| Repressor Proteins | 3 | 2017 | 3023 | 0.280 |
Why?
|
| Government Regulation | 2 | 2022 | 522 | 0.280 |
Why?
|
| Enzyme Inhibitors | 5 | 2021 | 3798 | 0.280 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 3 | 2022 | 912 | 0.280 |
Why?
|
| Transcription Factors | 7 | 2022 | 12208 | 0.280 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2016 | 503 | 0.270 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 1375 | 0.270 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2010 | 880 | 0.270 |
Why?
|
| Drug Administration Schedule | 5 | 2020 | 4933 | 0.270 |
Why?
|
| Recurrence | 3 | 2022 | 8340 | 0.270 |
Why?
|
| Mice | 37 | 2023 | 81183 | 0.270 |
Why?
|
| Gene Deletion | 5 | 2019 | 2751 | 0.270 |
Why?
|
| Scientific Misconduct | 2 | 2023 | 71 | 0.270 |
Why?
|
| Immunity, Cellular | 3 | 2022 | 1607 | 0.270 |
Why?
|
| Drug Combinations | 2 | 2022 | 1959 | 0.260 |
Why?
|
| Computational Biology | 2 | 2016 | 3521 | 0.260 |
Why?
|
| Immunity | 2 | 2022 | 1012 | 0.260 |
Why?
|
| Tissue Donors | 1 | 2015 | 2240 | 0.260 |
Why?
|
| Prophages | 2 | 2023 | 38 | 0.260 |
Why?
|
| Ethics, Professional | 2 | 2023 | 102 | 0.260 |
Why?
|
| Glycoproteins | 1 | 2013 | 2263 | 0.260 |
Why?
|
| Immunotherapy | 1 | 2020 | 4445 | 0.250 |
Why?
|
| Aspartic Acid | 2 | 2020 | 576 | 0.250 |
Why?
|
| Bacterial Vaccines | 2 | 2007 | 403 | 0.250 |
Why?
|
| Disulfides | 3 | 2019 | 457 | 0.250 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 2 | 2015 | 13 | 0.250 |
Why?
|
| Mass Screening | 1 | 2020 | 5255 | 0.250 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 1405 | 0.250 |
Why?
|
| Muramidase | 2 | 2019 | 174 | 0.240 |
Why?
|
| Government | 2 | 2022 | 165 | 0.240 |
Why?
|
| Europe | 2 | 2022 | 3339 | 0.240 |
Why?
|
| DNA-Directed RNA Polymerases | 3 | 2014 | 371 | 0.240 |
Why?
|
| History, 20th Century | 2 | 2023 | 2740 | 0.240 |
Why?
|
| Cholesterol | 1 | 2013 | 2917 | 0.240 |
Why?
|
| RNA, Messenger | 12 | 2020 | 13033 | 0.240 |
Why?
|
| Nuclear Warfare | 1 | 2023 | 31 | 0.230 |
Why?
|
| Anticoagulants | 4 | 2021 | 4599 | 0.230 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2013 | 4386 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2020 | 1375 | 0.230 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 252 | 0.230 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 13695 | 0.230 |
Why?
|
| Operon | 4 | 2024 | 363 | 0.220 |
Why?
|
| Hydrolysis | 4 | 2014 | 682 | 0.220 |
Why?
|
| Vibrio cholerae | 5 | 2014 | 806 | 0.220 |
Why?
|
| Mycobacterium leprae | 1 | 2003 | 94 | 0.220 |
Why?
|
| Brazil | 3 | 2021 | 1270 | 0.220 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 2012 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2021 | 23338 | 0.220 |
Why?
|
| Protein Conformation | 9 | 2020 | 4011 | 0.220 |
Why?
|
| Peptide Library | 2 | 2015 | 349 | 0.220 |
Why?
|
| Water Purification | 1 | 2023 | 48 | 0.220 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2023 | 98 | 0.220 |
Why?
|
| Chromosome Mapping | 6 | 2014 | 4740 | 0.220 |
Why?
|
| Multiprotein Complexes | 2 | 2008 | 1119 | 0.220 |
Why?
|
| Virus Physiological Phenomena | 1 | 2022 | 18 | 0.220 |
Why?
|
| Genes, jun | 5 | 1993 | 71 | 0.210 |
Why?
|
| Government Programs | 2 | 2021 | 275 | 0.210 |
Why?
|
| Group Practice | 1 | 2023 | 149 | 0.210 |
Why?
|
| Congresses as Topic | 3 | 2021 | 764 | 0.210 |
Why?
|
| Monkeypox virus | 1 | 2022 | 48 | 0.210 |
Why?
|
| Interleukin-6 | 5 | 2021 | 3200 | 0.210 |
Why?
|
| Asthma | 1 | 2021 | 6011 | 0.210 |
Why?
|
| Gene Targeting | 2 | 2003 | 880 | 0.210 |
Why?
|
| Immunity, Active | 1 | 2022 | 60 | 0.210 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2021 | 34 | 0.210 |
Why?
|
| Immune System | 1 | 2008 | 805 | 0.210 |
Why?
|
| Webcasts as Topic | 1 | 2022 | 15 | 0.210 |
Why?
|
| Qatar | 1 | 2021 | 36 | 0.210 |
Why?
|
| Biosynthetic Pathways | 2 | 2013 | 137 | 0.210 |
Why?
|
| RNA, Viral | 2 | 2020 | 2902 | 0.200 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 10180 | 0.200 |
Why?
|
| Bahamas | 1 | 2021 | 11 | 0.200 |
Why?
|
| Neoplasms | 4 | 2022 | 21683 | 0.200 |
Why?
|
| Peptides | 4 | 2023 | 4409 | 0.200 |
Why?
|
| Uridine | 1 | 2021 | 146 | 0.200 |
Why?
|
| Protein Binding | 11 | 2021 | 9386 | 0.200 |
Why?
|
| History, 19th Century | 1 | 2023 | 720 | 0.190 |
Why?
|
| Virginia | 1 | 2021 | 121 | 0.190 |
Why?
|
| Environmental Pollution | 1 | 2022 | 118 | 0.190 |
Why?
|
| Cell Cycle | 3 | 2021 | 2967 | 0.190 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 129 | 0.190 |
Why?
|
| DNA Replication | 4 | 2021 | 1399 | 0.190 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2219 | 0.190 |
Why?
|
| Crystallography, X-Ray | 6 | 2019 | 2011 | 0.190 |
Why?
|
| Ireland | 1 | 2021 | 161 | 0.190 |
Why?
|
| Self Administration | 8 | 2021 | 385 | 0.190 |
Why?
|
| Hong Kong | 1 | 2021 | 148 | 0.190 |
Why?
|
| Education, Distance | 2 | 2022 | 251 | 0.190 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2021 | 1213 | 0.190 |
Why?
|
| Consumer Product Safety | 1 | 2021 | 122 | 0.190 |
Why?
|
| Gene Expression | 5 | 2017 | 7799 | 0.190 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 2208 | 0.190 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 68 | 0.190 |
Why?
|
| Serology | 1 | 2020 | 7 | 0.190 |
Why?
|
| Amino Acid Sequence | 12 | 2015 | 13815 | 0.190 |
Why?
|
| Civil Rights | 1 | 2021 | 132 | 0.190 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2011 | 2849 | 0.190 |
Why?
|
| Genetic Complementation Test | 2 | 2014 | 562 | 0.180 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 370 | 0.180 |
Why?
|
| Quinazolines | 2 | 2021 | 1356 | 0.180 |
Why?
|
| Ships | 1 | 2020 | 61 | 0.180 |
Why?
|
| Carbon | 2 | 2022 | 687 | 0.180 |
Why?
|
| Iceland | 1 | 2020 | 183 | 0.180 |
Why?
|
| Compassionate Use Trials | 1 | 2020 | 46 | 0.180 |
Why?
|
| Bioethical Issues | 1 | 2021 | 124 | 0.180 |
Why?
|
| History, 18th Century | 1 | 2020 | 214 | 0.180 |
Why?
|
| Carboxy-Lyases | 1 | 2020 | 90 | 0.180 |
Why?
|
| Methylmalonyl-CoA Mutase | 1 | 2019 | 22 | 0.180 |
Why?
|
| Neutralization Tests | 1 | 2022 | 758 | 0.180 |
Why?
|
| Protein Interaction Mapping | 2 | 2014 | 627 | 0.180 |
Why?
|
| Population Surveillance | 2 | 2021 | 2616 | 0.180 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 241 | 0.180 |
Why?
|
| Quinolines | 1 | 2005 | 732 | 0.180 |
Why?
|
| Secretory Pathway | 2 | 2009 | 51 | 0.180 |
Why?
|
| Female | 42 | 2023 | 380194 | 0.180 |
Why?
|
| Civil Defense | 1 | 2021 | 109 | 0.180 |
Why?
|
| Immunization Schedule | 1 | 2021 | 221 | 0.180 |
Why?
|
| Hydrazines | 1 | 2021 | 226 | 0.180 |
Why?
|
| Folic Acid | 2 | 2019 | 1300 | 0.180 |
Why?
|
| Coenzyme A | 1 | 2019 | 39 | 0.180 |
Why?
|
| Vehicle Emissions | 2 | 2021 | 665 | 0.180 |
Why?
|
| Succinates | 1 | 2019 | 83 | 0.180 |
Why?
|
| Injections, Subcutaneous | 1 | 2021 | 666 | 0.180 |
Why?
|
| Recombination, Genetic | 3 | 2014 | 1586 | 0.180 |
Why?
|
| PDZ Domains | 1 | 2019 | 22 | 0.180 |
Why?
|
| Mannosyltransferases | 1 | 2019 | 23 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 4 | 2019 | 1655 | 0.180 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 4251 | 0.170 |
Why?
|
| BCG Vaccine | 3 | 2023 | 369 | 0.170 |
Why?
|
| Germany | 1 | 2022 | 862 | 0.170 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 121 | 0.170 |
Why?
|
| Proteomics | 4 | 2016 | 3638 | 0.170 |
Why?
|
| Washington | 1 | 2020 | 313 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2011 | 215 | 0.170 |
Why?
|
| Folic Acid Antagonists | 2 | 2013 | 84 | 0.170 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 1999 | 65 | 0.170 |
Why?
|
| Antacids | 1 | 2019 | 99 | 0.170 |
Why?
|
| Bacillus subtilis | 3 | 2019 | 359 | 0.170 |
Why?
|
| Treatment Failure | 3 | 2022 | 2618 | 0.170 |
Why?
|
| Radiology | 2 | 2023 | 2100 | 0.170 |
Why?
|
| Genetic Loci | 3 | 2020 | 2575 | 0.170 |
Why?
|
| Disease Models, Animal | 9 | 2022 | 18029 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2021 | 2942 | 0.170 |
Why?
|
| Health Status Disparities | 2 | 2021 | 1797 | 0.170 |
Why?
|
| Cyclonic Storms | 1 | 2021 | 119 | 0.170 |
Why?
|
| Ubiquitin | 1 | 2004 | 852 | 0.170 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 305 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 323 | 0.170 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 113 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2017 | 3597 | 0.170 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 137 | 0.170 |
Why?
|
| Nitrogen | 1 | 2020 | 344 | 0.170 |
Why?
|
| Azithromycin | 1 | 2020 | 196 | 0.170 |
Why?
|
| Coronavirus | 1 | 2021 | 158 | 0.170 |
Why?
|
| Amino Acid Substitution | 3 | 2014 | 1791 | 0.160 |
Why?
|
| Fluorescence | 2 | 2018 | 751 | 0.160 |
Why?
|
| Genomics | 6 | 2022 | 5720 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 12 | 2020 | 21827 | 0.160 |
Why?
|
| Enterotoxigenic Escherichia coli | 1 | 2018 | 32 | 0.160 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 418 | 0.160 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2013 | 312 | 0.160 |
Why?
|
| China | 2 | 2021 | 2248 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 17446 | 0.160 |
Why?
|
| Models, Molecular | 7 | 2019 | 5456 | 0.160 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 1312 | 0.160 |
Why?
|
| Health | 1 | 2021 | 394 | 0.160 |
Why?
|
| Religion | 1 | 2021 | 356 | 0.160 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2018 | 82 | 0.160 |
Why?
|
| Amoeba | 1 | 2018 | 21 | 0.160 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 323 | 0.160 |
Why?
|
| Oligosaccharides | 1 | 2020 | 414 | 0.160 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 430 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 374 | 0.160 |
Why?
|
| Piperazines | 4 | 2014 | 2488 | 0.160 |
Why?
|
| Genome, Viral | 1 | 2021 | 667 | 0.150 |
Why?
|
| ABO Blood-Group System | 1 | 2020 | 367 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2021 | 881 | 0.150 |
Why?
|
| Equipment and Supplies | 1 | 2020 | 281 | 0.150 |
Why?
|
| Policy | 1 | 2021 | 508 | 0.150 |
Why?
|
| New York City | 1 | 2020 | 710 | 0.150 |
Why?
|
| DNA-Binding Proteins | 8 | 2021 | 9648 | 0.150 |
Why?
|
| Drug Resistance, Microbial | 3 | 2019 | 862 | 0.150 |
Why?
|
| Resource Allocation | 1 | 2020 | 341 | 0.150 |
Why?
|
| Nasopharynx | 1 | 2020 | 379 | 0.150 |
Why?
|
| Mice, Mutant Strains | 2 | 2016 | 1866 | 0.150 |
Why?
|
| Adult | 29 | 2022 | 214055 | 0.150 |
Why?
|
| Leukemia, Myeloid | 5 | 1994 | 707 | 0.150 |
Why?
|
| Sex Factors | 2 | 2021 | 10397 | 0.150 |
Why?
|
| Administration, Oral | 3 | 2021 | 3913 | 0.150 |
Why?
|
| Fluoresceins | 1 | 2017 | 235 | 0.150 |
Why?
|
| Databases, Factual | 3 | 2021 | 7729 | 0.150 |
Why?
|
| Tongue | 1 | 2020 | 406 | 0.150 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2018 | 567 | 0.150 |
Why?
|
| Cell Cycle Proteins | 3 | 2019 | 3462 | 0.150 |
Why?
|
| Public Opinion | 1 | 2021 | 477 | 0.150 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 329 | 0.150 |
Why?
|
| Financing, Government | 1 | 2020 | 468 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 4 | 2019 | 944 | 0.140 |
Why?
|
| Breath Tests | 1 | 2018 | 280 | 0.140 |
Why?
|
| Penicillin V | 1 | 2016 | 18 | 0.140 |
Why?
|
| Open Reading Frames | 6 | 2006 | 810 | 0.140 |
Why?
|
| Francisella tularensis | 2 | 2007 | 56 | 0.140 |
Why?
|
| Benzofurans | 1 | 2017 | 140 | 0.140 |
Why?
|
| Small Molecule Libraries | 2 | 2019 | 720 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2020 | 541 | 0.140 |
Why?
|
| Amidohydrolases | 1 | 2017 | 169 | 0.140 |
Why?
|
| Standard of Care | 1 | 2020 | 564 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7279 | 0.140 |
Why?
|
| Receptors, Virus | 1 | 2020 | 648 | 0.140 |
Why?
|
| Nose | 1 | 2020 | 509 | 0.140 |
Why?
|
| Phosphorylation | 5 | 2016 | 8436 | 0.140 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2021 | 536 | 0.140 |
Why?
|
| Gene Silencing | 2 | 2017 | 1538 | 0.140 |
Why?
|
| Family Characteristics | 1 | 2021 | 1000 | 0.140 |
Why?
|
| Peptidyl Transferases | 1 | 2016 | 54 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 4479 | 0.140 |
Why?
|
| Cloning, Molecular | 4 | 2015 | 4320 | 0.140 |
Why?
|
| Hospital Administration | 1 | 2020 | 353 | 0.140 |
Why?
|
| Male | 38 | 2023 | 350118 | 0.140 |
Why?
|
| Drug Synergism | 4 | 2019 | 1792 | 0.140 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 560 | 0.140 |
Why?
|
| Antigens, Surface | 1 | 2020 | 1663 | 0.140 |
Why?
|
| Benzhydryl Compounds | 3 | 2021 | 845 | 0.140 |
Why?
|
| Glycosylation | 1 | 2019 | 1126 | 0.140 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2007 | 1121 | 0.140 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 737 | 0.140 |
Why?
|
| Cell Line | 8 | 2022 | 15997 | 0.130 |
Why?
|
| Protein Transport | 1 | 2021 | 1988 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 722 | 0.130 |
Why?
|
| Acylation | 2 | 2014 | 107 | 0.130 |
Why?
|
| Substrate Specificity | 3 | 2019 | 1801 | 0.130 |
Why?
|
| Medical Oncology | 3 | 2017 | 2265 | 0.130 |
Why?
|
| Advisory Committees | 1 | 2020 | 775 | 0.130 |
Why?
|
| Japan | 1 | 2020 | 1360 | 0.130 |
Why?
|
| Pseudomonas putida | 1 | 2015 | 46 | 0.130 |
Why?
|
| Ferrozine | 1 | 2015 | 1 | 0.130 |
Why?
|
| Safety Management | 1 | 2021 | 783 | 0.130 |
Why?
|
| Child Behavior | 1 | 2021 | 839 | 0.130 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2007 | 141 | 0.130 |
Why?
|
| Cross-Linking Reagents | 1 | 2018 | 694 | 0.130 |
Why?
|
| Polymyxin B | 1 | 2015 | 46 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1999 | 692 | 0.130 |
Why?
|
| Narcotic Antagonists | 2 | 2013 | 562 | 0.130 |
Why?
|
| Lactones | 1 | 2017 | 329 | 0.130 |
Why?
|
| Occupational Health | 1 | 2021 | 809 | 0.130 |
Why?
|
| Job Description | 1 | 2014 | 58 | 0.130 |
Why?
|
| Child, Preschool | 3 | 2022 | 41006 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 640 | 0.130 |
Why?
|
| Molecular Structure | 5 | 2021 | 1899 | 0.130 |
Why?
|
| Oxidoreductases | 1 | 2017 | 424 | 0.130 |
Why?
|
| Sequence Homology, Amino Acid | 6 | 2015 | 2839 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2023 | 1809 | 0.120 |
Why?
|
| Self Care | 1 | 2020 | 786 | 0.120 |
Why?
|
| Health Facilities | 1 | 2020 | 573 | 0.120 |
Why?
|
| India | 1 | 2021 | 2197 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2020 | 2971 | 0.120 |
Why?
|
| Arachidonic Acid | 1 | 2016 | 434 | 0.120 |
Why?
|
| Amines | 2 | 2007 | 276 | 0.120 |
Why?
|
| Phosphatidylethanolamines | 1 | 2015 | 134 | 0.120 |
Why?
|
| SELEX Aptamer Technique | 1 | 2014 | 19 | 0.120 |
Why?
|
| Cell Growth Processes | 1 | 2015 | 399 | 0.120 |
Why?
|
| Epsilonproteobacteria | 1 | 2014 | 1 | 0.120 |
Why?
|
| Amide Synthases | 1 | 2014 | 12 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2016 | 1572 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2018 | 532 | 0.120 |
Why?
|
| Teichoic Acids | 1 | 2014 | 66 | 0.120 |
Why?
|
| Sugar Acids | 1 | 2014 | 24 | 0.120 |
Why?
|
| Membrane Proteins | 6 | 2019 | 7880 | 0.120 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 112 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 3 | 2013 | 1148 | 0.120 |
Why?
|
| Vaccinia virus | 2 | 2013 | 349 | 0.120 |
Why?
|
| Gene Order | 1 | 2014 | 176 | 0.120 |
Why?
|
| Endonucleases | 1 | 2017 | 380 | 0.120 |
Why?
|
| Risk Factors | 4 | 2022 | 72290 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 591 | 0.120 |
Why?
|
| Asparagine | 1 | 2014 | 122 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2019 | 1219 | 0.120 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2007 | 449 | 0.120 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2014 | 89 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 2948 | 0.120 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2015 | 179 | 0.120 |
Why?
|
| Motivation | 5 | 2018 | 1971 | 0.110 |
Why?
|
| Biological Assay | 1 | 2016 | 652 | 0.110 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 274 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2004 | 3703 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 941 | 0.110 |
Why?
|
| Adolescent | 4 | 2022 | 85781 | 0.110 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2013 | 109 | 0.110 |
Why?
|
| Protein Multimerization | 2 | 2019 | 970 | 0.110 |
Why?
|
| Coumarins | 1 | 2013 | 119 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2020 | 1403 | 0.110 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2013 | 143 | 0.110 |
Why?
|
| Dextroamphetamine | 1 | 2013 | 129 | 0.110 |
Why?
|
| Binding Sites | 6 | 2021 | 6114 | 0.110 |
Why?
|
| Phylogeny | 4 | 2023 | 2803 | 0.110 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 808 | 0.110 |
Why?
|
| Brain | 2 | 2018 | 26385 | 0.110 |
Why?
|
| Autoantibodies | 1 | 2021 | 2035 | 0.110 |
Why?
|
| Aptamers, Nucleotide | 1 | 2014 | 166 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11366 | 0.110 |
Why?
|
| Zebrafish | 4 | 2021 | 2994 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 2503 | 0.110 |
Why?
|
| RNA Interference | 5 | 2011 | 2889 | 0.110 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 1970 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2022 | 2684 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 689 | 0.110 |
Why?
|
| Organizational Policy | 1 | 2014 | 429 | 0.100 |
Why?
|
| RNA, Untranslated | 2 | 2013 | 453 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 434 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2021 | 1102 | 0.100 |
Why?
|
| Carrier Proteins | 2 | 2010 | 5021 | 0.100 |
Why?
|
| Magnesium | 2 | 2015 | 813 | 0.100 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 1177 | 0.100 |
Why?
|
| Reward | 1 | 2018 | 941 | 0.100 |
Why?
|
| Adenosine Diphosphate Ribose | 2 | 1989 | 63 | 0.100 |
Why?
|
| Phagocytosis | 2 | 2009 | 1539 | 0.100 |
Why?
|
| Ambulatory Care | 2 | 2021 | 2708 | 0.100 |
Why?
|
| Gastritis | 1 | 2013 | 196 | 0.100 |
Why?
|
| Elongation Factor 2 Kinase | 1 | 2011 | 10 | 0.100 |
Why?
|
| Genome | 3 | 2023 | 1808 | 0.100 |
Why?
|
| Salmonella typhimurium | 1 | 2013 | 351 | 0.100 |
Why?
|
| ADP Ribose Transferases | 2 | 1989 | 90 | 0.100 |
Why?
|
| Psychological Theory | 1 | 2012 | 168 | 0.100 |
Why?
|
| Heat Stress Disorders | 2 | 2021 | 50 | 0.100 |
Why?
|
| Immediate-Early Proteins | 3 | 2004 | 453 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2015 | 791 | 0.100 |
Why?
|
| Protein Kinase C | 3 | 1992 | 1227 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1889 | 0.100 |
Why?
|
| Naltrexone | 1 | 2013 | 307 | 0.100 |
Why?
|
| GTP-Binding Proteins | 3 | 1995 | 970 | 0.100 |
Why?
|
| Carbon-Nitrogen Ligases | 1 | 2010 | 28 | 0.090 |
Why?
|
| Genetic Techniques | 2 | 2017 | 435 | 0.090 |
Why?
|
| Chemokines | 2 | 2013 | 970 | 0.090 |
Why?
|
| Glutamine | 1 | 2014 | 578 | 0.090 |
Why?
|
| Cross Infection | 1 | 2020 | 1416 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 4186 | 0.090 |
Why?
|
| Cell Membrane | 2 | 2012 | 3748 | 0.090 |
Why?
|
| Signal Transduction | 9 | 2016 | 23403 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2015 | 965 | 0.090 |
Why?
|
| Games, Experimental | 1 | 2010 | 32 | 0.090 |
Why?
|
| Proto-Oncogenes | 1 | 1991 | 321 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 6622 | 0.090 |
Why?
|
| Gastric Mucosa | 1 | 2013 | 599 | 0.090 |
Why?
|
| Catalytic Domain | 3 | 2019 | 698 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 5853 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 19905 | 0.090 |
Why?
|
| NAD | 1 | 2014 | 593 | 0.090 |
Why?
|
| Education, Medical | 1 | 2022 | 1721 | 0.090 |
Why?
|
| Haemophilus influenzae | 2 | 2002 | 171 | 0.090 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2010 | 72 | 0.090 |
Why?
|
| Helicobacter Infections | 1 | 2013 | 386 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2282 | 0.090 |
Why?
|
| Epidermis | 1 | 2013 | 528 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2018 | 5974 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 5 | 2015 | 5867 | 0.090 |
Why?
|
| Transaminases | 1 | 2010 | 199 | 0.090 |
Why?
|
| Etoposide | 1 | 1991 | 641 | 0.090 |
Why?
|
| Rabbits | 1 | 2016 | 4894 | 0.090 |
Why?
|
| Botulinum Toxins | 2 | 1989 | 191 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 2026 | 0.090 |
Why?
|
| Risk | 1 | 2022 | 9687 | 0.090 |
Why?
|
| Research Subjects | 1 | 2011 | 239 | 0.090 |
Why?
|
| Mycobacterium fortuitum | 2 | 2005 | 5 | 0.080 |
Why?
|
| Clostridium botulinum | 2 | 1989 | 21 | 0.080 |
Why?
|
| Health Behavior | 1 | 2021 | 2636 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2021 | 10943 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 4 | 2014 | 3846 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2007 | 5179 | 0.080 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2012 | 794 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2020 | 1479 | 0.080 |
Why?
|
| Drug Resistance | 2 | 1994 | 1609 | 0.080 |
Why?
|
| Decision Making | 1 | 2022 | 3887 | 0.080 |
Why?
|
| Macaca mulatta | 1 | 2015 | 2375 | 0.080 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 272 | 0.080 |
Why?
|
| Aconitate Hydratase | 1 | 2008 | 15 | 0.080 |
Why?
|
| Conjugation, Genetic | 2 | 1999 | 126 | 0.080 |
Why?
|
| Virus Latency | 1 | 2011 | 358 | 0.080 |
Why?
|
| Point Mutation | 1 | 1994 | 1623 | 0.080 |
Why?
|
| Ethidium | 1 | 2007 | 27 | 0.080 |
Why?
|
| Dopamine Agonists | 1 | 2011 | 355 | 0.080 |
Why?
|
| Pentosyltransferases | 1 | 1988 | 65 | 0.080 |
Why?
|
| Drug Tolerance | 3 | 2019 | 376 | 0.080 |
Why?
|
| Models, Biological | 4 | 2018 | 9583 | 0.080 |
Why?
|
| Glutamic Acid | 1 | 2014 | 1169 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2021 | 5788 | 0.080 |
Why?
|
| Staphylococcus aureus | 2 | 2014 | 1451 | 0.080 |
Why?
|
| Kinetics | 5 | 2018 | 6473 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3679 | 0.080 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 3537 | 0.080 |
Why?
|
| Quinolones | 1 | 2011 | 367 | 0.080 |
Why?
|
| Skin | 1 | 2021 | 4364 | 0.080 |
Why?
|
| Fish Diseases | 1 | 2007 | 38 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 5 | 2017 | 6386 | 0.070 |
Why?
|
| Carbohydrate Sequence | 1 | 2007 | 414 | 0.070 |
Why?
|
| Critical Care | 1 | 2020 | 2647 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2018 | 2008 | 0.070 |
Why?
|
| Transduction, Genetic | 2 | 2009 | 913 | 0.070 |
Why?
|
| Culture Media | 3 | 2014 | 908 | 0.070 |
Why?
|
| Immunity, Innate | 3 | 2019 | 2958 | 0.070 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 494 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2021 | 4234 | 0.070 |
Why?
|
| Tularemia | 1 | 2007 | 36 | 0.070 |
Why?
|
| Genotype | 1 | 2021 | 12951 | 0.070 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2019 | 165 | 0.070 |
Why?
|
| Molecular Chaperones | 2 | 2022 | 742 | 0.070 |
Why?
|
| Adhesins, Bacterial | 1 | 2007 | 119 | 0.070 |
Why?
|
| Interferons | 1 | 2010 | 706 | 0.070 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2006 | 19 | 0.070 |
Why?
|
| Sulfates | 1 | 2007 | 390 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 3229 | 0.070 |
Why?
|
| Conserved Sequence | 1 | 2010 | 1202 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2022 | 21746 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2007 | 464 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2022 | 4687 | 0.070 |
Why?
|
| Enzyme Activation | 4 | 2018 | 3701 | 0.070 |
Why?
|
| Progesterone | 1 | 2010 | 776 | 0.070 |
Why?
|
| Autophagy | 2 | 2011 | 1300 | 0.070 |
Why?
|
| Marijuana Abuse | 2 | 2011 | 403 | 0.070 |
Why?
|
| Internationality | 2 | 2023 | 1003 | 0.070 |
Why?
|
| GABA Agonists | 1 | 2006 | 111 | 0.070 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2006 | 212 | 0.070 |
Why?
|
| Drosophila melanogaster | 2 | 2005 | 1708 | 0.070 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2008 | 433 | 0.070 |
Why?
|
| Luminescent Proteins | 2 | 2010 | 853 | 0.070 |
Why?
|
| Polyketide Synthases | 2 | 2017 | 28 | 0.070 |
Why?
|
| Lung | 2 | 2023 | 9856 | 0.070 |
Why?
|
| Phenothiazines | 1 | 2005 | 63 | 0.070 |
Why?
|
| Genomic Instability | 1 | 2010 | 695 | 0.070 |
Why?
|
| Cisplatin | 1 | 1992 | 1662 | 0.070 |
Why?
|
| O Antigens | 1 | 2007 | 193 | 0.070 |
Why?
|
| ROC Curve | 1 | 2013 | 3527 | 0.070 |
Why?
|
| Cell Survival | 3 | 2008 | 5882 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1519 | 0.060 |
Why?
|
| RNA Processing, Post-Transcriptional | 3 | 2023 | 436 | 0.060 |
Why?
|
| Endosomes | 1 | 2008 | 520 | 0.060 |
Why?
|
| Pyrroles | 1 | 2011 | 1146 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2564 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2020 | 9146 | 0.060 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2006 | 168 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 789 | 0.060 |
Why?
|
| Silver Staining | 1 | 2004 | 64 | 0.060 |
Why?
|
| Heroin Dependence | 1 | 2005 | 175 | 0.060 |
Why?
|
| Biological Transport | 2 | 2009 | 2118 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 12959 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-jun | 4 | 1995 | 286 | 0.060 |
Why?
|
| Genes, Insect | 1 | 2005 | 268 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15076 | 0.060 |
Why?
|
| Iron-Binding Proteins | 1 | 2004 | 79 | 0.060 |
Why?
|
| Neuroprotective Agents | 2 | 2009 | 941 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2759 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 9 | 1995 | 6314 | 0.060 |
Why?
|
| Embryo, Nonmammalian | 1 | 2007 | 895 | 0.060 |
Why?
|
| Aged | 7 | 2023 | 163280 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2011 | 4217 | 0.060 |
Why?
|
| Cell Nucleus | 5 | 2009 | 2969 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2013 | 1333 | 0.060 |
Why?
|
| Family Leave | 1 | 2023 | 18 | 0.060 |
Why?
|
| Middle Aged | 15 | 2023 | 213383 | 0.060 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2004 | 195 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3086 | 0.060 |
Why?
|
| Genetic Engineering | 2 | 2008 | 951 | 0.060 |
Why?
|
| Transfection | 3 | 2011 | 5892 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2004 | 168 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2008 | 2699 | 0.060 |
Why?
|
| Listeria monocytogenes | 1 | 2005 | 250 | 0.060 |
Why?
|
| Heterozygote | 1 | 2010 | 2804 | 0.060 |
Why?
|
| Temperament | 1 | 2005 | 283 | 0.060 |
Why?
|
| Double-Blind Method | 6 | 2021 | 12026 | 0.060 |
Why?
|
| Methadone | 1 | 2005 | 306 | 0.060 |
Why?
|
| Ethers, Cyclic | 2 | 1993 | 33 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 1801 | 0.060 |
Why?
|
| Heart Rate | 6 | 2011 | 4091 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 2017 | 226 | 0.050 |
Why?
|
| Bacterial Load | 2 | 2014 | 153 | 0.050 |
Why?
|
| Physicians | 1 | 2021 | 4567 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 3129 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 2 | 2021 | 839 | 0.050 |
Why?
|
| DNA Primers | 4 | 2012 | 2892 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2005 | 1030 | 0.050 |
Why?
|
| Lac Operon | 1 | 2002 | 238 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2009 | 1547 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 595 | 0.050 |
Why?
|
| Ice | 1 | 2023 | 104 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2002 | 193 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 2088 | 0.050 |
Why?
|
| Gene Expression Regulation | 5 | 2004 | 12072 | 0.050 |
Why?
|
| Vero Cells | 2 | 2021 | 485 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 380 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 563 | 0.050 |
Why?
|
| Dimerization | 2 | 2014 | 893 | 0.050 |
Why?
|
| Phosphates | 1 | 2005 | 786 | 0.050 |
Why?
|
| Receptors, Immunologic | 2 | 2005 | 1423 | 0.050 |
Why?
|
| Warfarin | 1 | 2009 | 1496 | 0.050 |
Why?
|
| Salmonella | 1 | 2021 | 129 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 927 | 0.050 |
Why?
|
| Zea mays | 1 | 2001 | 105 | 0.050 |
Why?
|
| Personality Disorders | 1 | 2005 | 713 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2009 | 3494 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2004 | 1682 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2011 | 4554 | 0.050 |
Why?
|
| Drosophila | 2 | 2008 | 1491 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 5535 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 5524 | 0.050 |
Why?
|
| Markov Chains | 2 | 2014 | 969 | 0.050 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2021 | 407 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2011 | 2725 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2011 | 9734 | 0.050 |
Why?
|
| Software | 1 | 2014 | 4443 | 0.050 |
Why?
|
| Muscidae | 1 | 1999 | 2 | 0.050 |
Why?
|
| Deoxyadenosines | 1 | 2019 | 27 | 0.050 |
Why?
|
| Molecular Weight | 3 | 1994 | 2255 | 0.050 |
Why?
|
| Genes, fos | 4 | 1993 | 183 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2001 | 1085 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 11524 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2011 | 3474 | 0.040 |
Why?
|
| Mycobacterium kansasii | 1 | 2019 | 11 | 0.040 |
Why?
|
| Health Occupations | 1 | 2021 | 224 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2005 | 2716 | 0.040 |
Why?
|
| Database Management Systems | 1 | 2001 | 270 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2019 | 2557 | 0.040 |
Why?
|
| Intercalating Agents | 1 | 1999 | 34 | 0.040 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 2029 | 0.040 |
Why?
|
| Token Economy | 2 | 2011 | 17 | 0.040 |
Why?
|
| Cytosol | 2 | 2018 | 901 | 0.040 |
Why?
|
| Rhodobacter capsulatus | 1 | 1999 | 11 | 0.040 |
Why?
|
| Aging | 1 | 2018 | 8664 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2010 | 4161 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2019 | 293 | 0.040 |
Why?
|
| Biocatalysis | 1 | 2019 | 167 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2019 | 87 | 0.040 |
Why?
|
| Cannabis | 1 | 2006 | 439 | 0.040 |
Why?
|
| Propionates | 1 | 2019 | 169 | 0.040 |
Why?
|
| Edeine | 1 | 2018 | 2 | 0.040 |
Why?
|
| Aminoacylation | 1 | 2018 | 10 | 0.040 |
Why?
|
| Bacteriophage lambda | 1 | 1999 | 147 | 0.040 |
Why?
|
| Cyanobacteria | 1 | 1999 | 49 | 0.040 |
Why?
|
| Streptomycin | 1 | 2018 | 69 | 0.040 |
Why?
|
| Escherichia coli Vaccines | 1 | 2018 | 11 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2019 | 83 | 0.040 |
Why?
|
| Streptomyces | 1 | 1999 | 89 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2009 | 4199 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2003 | 1526 | 0.040 |
Why?
|
| Blood Pressure | 6 | 2011 | 8554 | 0.040 |
Why?
|
| Aminoacyltransferases | 1 | 2018 | 51 | 0.040 |
Why?
|
| Bacillus | 1 | 2018 | 77 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2019 | 331 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 404 | 0.040 |
Why?
|
| Ethics Committees, Research | 1 | 2020 | 194 | 0.040 |
Why?
|
| Chromatography, Thin Layer | 1 | 2018 | 223 | 0.040 |
Why?
|
| Health Status | 2 | 2021 | 4034 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 15519 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2018 | 425 | 0.040 |
Why?
|
| Actins | 3 | 1992 | 2121 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5221 | 0.040 |
Why?
|
| Apoptosis | 2 | 2011 | 9727 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 1338 | 0.040 |
Why?
|
| Monocytes | 3 | 2013 | 2596 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1993 | 821 | 0.040 |
Why?
|
| Phenylalanine | 1 | 1999 | 365 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2020 | 434 | 0.040 |
Why?
|
| Risk Management | 1 | 2021 | 571 | 0.040 |
Why?
|
| Carbazoles | 1 | 1999 | 226 | 0.040 |
Why?
|
| Amoxicillin | 1 | 2018 | 170 | 0.040 |
Why?
|
| Streptococcus thermophilus | 1 | 2017 | 19 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 361 | 0.040 |
Why?
|
| DNA Damage | 3 | 1999 | 2432 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2018 | 224 | 0.040 |
Why?
|
| Leucovorin | 1 | 1999 | 628 | 0.040 |
Why?
|
| Administration, Inhalation | 2 | 2010 | 1105 | 0.040 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1997 | 293 | 0.040 |
Why?
|
| Sequence Alignment | 2 | 2012 | 2256 | 0.040 |
Why?
|
| Glioma | 1 | 2011 | 3401 | 0.040 |
Why?
|
| Vitamin B 12 | 1 | 2019 | 527 | 0.040 |
Why?
|
| Employment | 1 | 2023 | 1132 | 0.040 |
Why?
|
| Transcription Initiation Site | 1 | 2017 | 196 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2011 | 16689 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2011 | 783 | 0.030 |
Why?
|
| Immune Evasion | 1 | 2019 | 360 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2018 | 227 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2019 | 959 | 0.030 |
Why?
|
| Benzoic Acid | 1 | 2015 | 15 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 1703 | 0.030 |
Why?
|
| Affect | 2 | 2018 | 1476 | 0.030 |
Why?
|
| Fenofibrate | 1 | 1996 | 88 | 0.030 |
Why?
|
| Cues | 1 | 2021 | 873 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2017 | 590 | 0.030 |
Why?
|
| Health Priorities | 1 | 2019 | 380 | 0.030 |
Why?
|
| Xenopus | 2 | 2007 | 712 | 0.030 |
Why?
|
| Epitopes | 1 | 2002 | 2571 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 768 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2011 | 3481 | 0.030 |
Why?
|
| Enterotoxins | 2 | 1995 | 368 | 0.030 |
Why?
|
| Serine | 1 | 1999 | 826 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2002 | 2234 | 0.030 |
Why?
|
| Glucosides | 1 | 1999 | 451 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 4328 | 0.030 |
Why?
|
| Agar | 1 | 2015 | 56 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2004 | 2258 | 0.030 |
Why?
|
| Environment | 1 | 2021 | 1124 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 1996 | 281 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 4258 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2014 | 43 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 2 | 2011 | 205 | 0.030 |
Why?
|
| HIV Infections | 1 | 2021 | 16718 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 940 | 0.030 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2015 | 129 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2020 | 899 | 0.030 |
Why?
|
| beta-Lactams | 1 | 2016 | 160 | 0.030 |
Why?
|
| Facial Expression | 1 | 2018 | 508 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1995 | 380 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 1999 | 826 | 0.030 |
Why?
|
| Neutropenia | 2 | 2002 | 895 | 0.030 |
Why?
|
| Streptococcus pyogenes | 1 | 2017 | 289 | 0.030 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1995 | 121 | 0.030 |
Why?
|
| Breast | 1 | 2023 | 1969 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2009 | 4420 | 0.030 |
Why?
|
| Lysosomes | 1 | 2019 | 893 | 0.030 |
Why?
|
| Electron Transport | 1 | 2015 | 211 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2020 | 766 | 0.030 |
Why?
|
| Species Specificity | 2 | 2009 | 2478 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 1504 | 0.030 |
Why?
|
| Moral Obligations | 1 | 1995 | 96 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2014 | 305 | 0.030 |
Why?
|
| Fluorouracil | 1 | 1999 | 1619 | 0.030 |
Why?
|
| Biofilms | 1 | 2018 | 617 | 0.030 |
Why?
|
| Half-Life | 1 | 1995 | 661 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2017 | 403 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 281 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 2 | 2008 | 377 | 0.030 |
Why?
|
| RNA, Double-Stranded | 2 | 2005 | 290 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1992 | 236 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1995 | 494 | 0.030 |
Why?
|
| Dihydropteroate Synthase | 1 | 2013 | 27 | 0.030 |
Why?
|
| Gene Dosage | 1 | 1998 | 1252 | 0.030 |
Why?
|
| Law Enforcement | 1 | 1995 | 109 | 0.030 |
Why?
|
| Peroxynitrous Acid | 1 | 2013 | 41 | 0.030 |
Why?
|
| Reactive Nitrogen Species | 1 | 2013 | 35 | 0.030 |
Why?
|
| Skin Diseases, Viral | 1 | 2013 | 21 | 0.030 |
Why?
|
| Clone Cells | 2 | 1994 | 1692 | 0.030 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2015 | 198 | 0.030 |
Why?
|
| Clostridium | 2 | 1995 | 98 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2010 | 632 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2015 | 229 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 1998 | 714 | 0.030 |
Why?
|
| Cattle | 2 | 2011 | 3922 | 0.030 |
Why?
|
| Vaccinia | 1 | 2013 | 76 | 0.030 |
Why?
|
| Checklist | 1 | 2020 | 833 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2005 | 3748 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2015 | 413 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 1786 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1992 | 118 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1992 | 58 | 0.030 |
Why?
|
| Reserpine | 1 | 2011 | 66 | 0.030 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2011 | 24 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2013 | 249 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13102 | 0.030 |
Why?
|
| Chymotrypsin | 1 | 2012 | 149 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 2494 | 0.030 |
Why?
|
| Radiography | 1 | 2023 | 7023 | 0.030 |
Why?
|
| Codon | 1 | 1994 | 611 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 2 | 1995 | 293 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 3505 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 2013 | 291 | 0.030 |
Why?
|
| Social Behavior | 1 | 2018 | 1127 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2013 | 311 | 0.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2007 | 3658 | 0.030 |
Why?
|
| Learning | 1 | 2021 | 1713 | 0.030 |
Why?
|
| Genomic Library | 1 | 2011 | 193 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 1994 | 551 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 1996 | 604 | 0.020 |
Why?
|
| HIV-1 | 1 | 2009 | 6939 | 0.020 |
Why?
|
| Behavioral Research | 1 | 2011 | 54 | 0.020 |
Why?
|
| Lipid Bilayers | 1 | 2013 | 381 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 809 | 0.020 |
Why?
|
| Diarrhea | 1 | 2018 | 1348 | 0.020 |
Why?
|
| Inpatients | 1 | 2023 | 2518 | 0.020 |
Why?
|
| Threonine | 1 | 2012 | 279 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 56 | 0.020 |
Why?
|
| Verapamil | 1 | 2011 | 244 | 0.020 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2013 | 271 | 0.020 |
Why?
|
| Reinforcement Schedule | 1 | 2011 | 129 | 0.020 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2010 | 22 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1993 | 337 | 0.020 |
Why?
|
| Trans-Activators | 2 | 2015 | 2924 | 0.020 |
Why?
|
| Indoles | 1 | 1999 | 1839 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 711 | 0.020 |
Why?
|
| Cholera | 1 | 1997 | 785 | 0.020 |
Why?
|
| Motor Activity | 1 | 2021 | 2714 | 0.020 |
Why?
|
| Isomerism | 1 | 2010 | 201 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2011 | 719 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2010 | 210 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 1994 | 2050 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2011 | 577 | 0.020 |
Why?
|
| Alcoholism | 1 | 2021 | 1906 | 0.020 |
Why?
|
| Cytoskeleton | 2 | 2005 | 1185 | 0.020 |
Why?
|
| DNA | 2 | 2001 | 7301 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1995 | 1285 | 0.020 |
Why?
|
| DNA, Neoplasm | 2 | 1992 | 1758 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1997 | 1900 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2007 | 4644 | 0.020 |
Why?
|
| RNA, Neoplasm | 4 | 1992 | 769 | 0.020 |
Why?
|
| Smoke | 1 | 2011 | 227 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2011 | 497 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 1991 | 374 | 0.020 |
Why?
|
| Intestines | 1 | 2018 | 1924 | 0.020 |
Why?
|
| Rhodococcus | 1 | 2008 | 14 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2011 | 844 | 0.020 |
Why?
|
| Alcohol-Related Disorders | 1 | 2011 | 234 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 300 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 557 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2013 | 798 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 1992 | 651 | 0.020 |
Why?
|
| Caspases | 1 | 2012 | 928 | 0.020 |
Why?
|
| Travel | 1 | 2014 | 788 | 0.020 |
Why?
|
| Isoelectric Point | 1 | 1988 | 80 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 1993 | 8428 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 767 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2020 | 19229 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1995 | 1836 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2727 | 0.020 |
Why?
|
| Isoenzymes | 1 | 1992 | 1726 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 1991 | 640 | 0.020 |
Why?
|
| Self Report | 1 | 2018 | 3558 | 0.020 |
Why?
|
| Genomic Islands | 1 | 2007 | 51 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2008 | 277 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2020 | 5985 | 0.020 |
Why?
|
| Prevalence | 2 | 2019 | 15226 | 0.020 |
Why?
|
| Euphoria | 1 | 2007 | 67 | 0.020 |
Why?
|
| Smell | 1 | 2009 | 244 | 0.020 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2008 | 144 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1997 | 4026 | 0.020 |
Why?
|
| Cyclohexanols | 1 | 2007 | 127 | 0.020 |
Why?
|
| Hormones | 1 | 2010 | 889 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1988 | 440 | 0.020 |
Why?
|
| Gambling | 1 | 2010 | 250 | 0.020 |
Why?
|
| Laboratories | 1 | 2010 | 463 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 1086 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2008 | 246 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2018 | 3690 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 1157 | 0.020 |
Why?
|
| Globins | 1 | 1987 | 415 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2010 | 811 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 1708 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2013 | 832 | 0.020 |
Why?
|
| Meiosis | 1 | 1988 | 339 | 0.020 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2005 | 81 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 2171 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 688 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 2025 | 0.020 |
Why?
|
| Adenosine | 1 | 2010 | 825 | 0.020 |
Why?
|
| Anemia | 1 | 1995 | 1506 | 0.020 |
Why?
|
| Neutrophils | 1 | 2018 | 3719 | 0.020 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 121 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1991 | 2421 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1994 | 2455 | 0.020 |
Why?
|
| Transport Vesicles | 1 | 2005 | 83 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 2309 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 8324 | 0.020 |
Why?
|
| Vacuoles | 1 | 2005 | 230 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2009 | 1216 | 0.020 |
Why?
|
| Galactans | 1 | 2004 | 31 | 0.020 |
Why?
|
| Antibodies, Bacterial | 2 | 2007 | 1470 | 0.020 |
Why?
|
| Genome, Human | 1 | 1997 | 4420 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 318 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1999 | 5172 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 3689 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 2187 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1992 | 1376 | 0.010 |
Why?
|
| DNA Repair | 1 | 2013 | 2046 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 2 | 1995 | 140 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2017 | 3444 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2011 | 3002 | 0.010 |
Why?
|
| Mental Health Services | 1 | 1995 | 1643 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 3760 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1993 | 222 | 0.010 |
Why?
|
| Methylphenidate | 1 | 2007 | 473 | 0.010 |
Why?
|
| Okadaic Acid | 2 | 1993 | 67 | 0.010 |
Why?
|
| Cysteine | 1 | 2007 | 874 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 964 | 0.010 |
Why?
|
| X-Rays | 2 | 1994 | 301 | 0.010 |
Why?
|
| Genes | 1 | 1987 | 1893 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 2009 | 2025 | 0.010 |
Why?
|
| Dactinomycin | 2 | 1992 | 318 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13284 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1994 | 708 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2004 | 354 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2005 | 1590 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 2109 | 0.010 |
Why?
|
| Research | 1 | 2010 | 1999 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2014 | 6196 | 0.010 |
Why?
|
| Arousal | 1 | 2007 | 1165 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 2004 | 582 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 565 | 0.010 |
Why?
|
| Cell Movement | 1 | 2013 | 5217 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 592 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 1901 | 0.010 |
Why?
|
| Liver | 1 | 1996 | 7474 | 0.010 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2004 | 571 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 1992 | 575 | 0.010 |
Why?
|
| Patient Admission | 1 | 2007 | 1380 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 11124 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2006 | 1106 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2005 | 1530 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2013 | 5102 | 0.010 |
Why?
|
| Mitochondria | 1 | 2011 | 3520 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2011 | 6442 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2007 | 3420 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 1997 | 122 | 0.010 |
Why?
|
| Ecology | 1 | 1997 | 106 | 0.010 |
Why?
|
| Immunoelectrophoresis | 1 | 1996 | 110 | 0.010 |
Why?
|
| Apolipoprotein A-II | 1 | 1996 | 39 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29063 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1997 | 718 | 0.010 |
Why?
|
| Moral Development | 1 | 1995 | 13 | 0.010 |
Why?
|
| Virus Integration | 1 | 1997 | 299 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2004 | 2132 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 1997 | 468 | 0.010 |
Why?
|
| Transferrin | 1 | 1996 | 295 | 0.010 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 1995 | 91 | 0.010 |
Why?
|
| Genes, Immediate-Early | 1 | 1995 | 101 | 0.010 |
Why?
|
| Cholera Toxin | 1 | 1997 | 556 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1994 | 91 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 2866 | 0.010 |
Why?
|
| Criminal Law | 1 | 1995 | 96 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1996 | 841 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 40561 | 0.010 |
Why?
|
| Pokeweed Mitogens | 1 | 1993 | 38 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 1994 | 216 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 2916 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1995 | 1101 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1995 | 452 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3768 | 0.010 |
Why?
|
| Cesium Radioisotopes | 1 | 1992 | 36 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1993 | 203 | 0.010 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1992 | 57 | 0.010 |
Why?
|
| Gene Conversion | 1 | 1992 | 71 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 13881 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1992 | 290 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1992 | 347 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 1224 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 56430 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 878 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 35421 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1992 | 320 | 0.010 |
Why?
|
| Anxiety | 1 | 2006 | 4297 | 0.010 |
Why?
|
| Isoquinolines | 1 | 1992 | 367 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1991 | 427 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1997 | 2225 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1992 | 585 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 8863 | 0.010 |
Why?
|
| Lod Score | 1 | 1991 | 614 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 14557 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 1988 | 77 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1992 | 802 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1991 | 798 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 24260 | 0.010 |
Why?
|
| Cytotoxins | 1 | 1988 | 153 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1996 | 6365 | 0.000 |
Why?
|
| Embryonic and Fetal Development | 1 | 1987 | 438 | 0.000 |
Why?
|
| Pregnancy in Diabetics | 1 | 1987 | 179 | 0.000 |
Why?
|
| Cell Differentiation | 2 | 1993 | 11483 | 0.000 |
Why?
|
| Sheep | 1 | 1987 | 1437 | 0.000 |
Why?
|
| Methylation | 1 | 1987 | 1106 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1992 | 3772 | 0.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1992 | 1378 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1987 | 1318 | 0.000 |
Why?
|
| Gestational Age | 1 | 1987 | 3493 | 0.000 |
Why?
|
| Infant, Premature | 1 | 1987 | 2044 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 57776 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1987 | 25625 | 0.000 |
Why?
|